Figure 2.

Relative expression of miR-23b in MM and WM tumor cells. (a) Box plot representation of mir-23b expression using Affimetrix Platform in a cohort of 38 multiple myeloma (MM) and 18 plasma cell leukemia (PCL) patients compared with normal PCs. (b) qRT–PCR analysis of miR-23b expression in a panel of MM cell lines (n=15), peripheral blood mononuclear cell (n=4) and BMSCs (n=3) from MM patients, CD138⁺ from MM patients (n=12) and PCL patients (n=3). (c) Expression of miR-23b in WM primary cells compared with normal CD19⁺ cells. (d) MM and WM cell lines were treated either with 10 ng/ml of IL-6, 100 ng/ml IL-17 or supernatant from tumor-derived BMSC suppressed the expression of miR-23b for 24 h. miR-23b expression was assessed by qRT–PCR using RNU44 as a loading control. Abbreviations: BMSC, bone marrow stromal cell; qRT–PCR, quantitative reverse transcriptase–PCR.